Clinical Trial Update: Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating aripiprazole as an adjunct to atypical antipsychotics for weight reduction and metabolic improvement in patients experiencing weight ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome Associated with Antipsychotic Therapy
• Weight Gain Associated with Antipsychotic Use

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Institute of Mental Health, Singapore | Conditions: Antipsychotics Weight Gain | Phase 4 | Status: COMPLETED